Abstract
INTRODUCTION
Hepatitis C virus (HCV) is a member of the flaviviridae family. HCV infection is a major public health challenge, with an estimated number of 130 to 170 million individuals infected worldwide [1, 2] . HCV causes acute and chronic hepatitis, and also leads to permanent liver damage and hepatocellular carcinoma in a signifi cant number of patients, via oxidative stress, insulin resistance, fibrosis, liver cirrhosis, and HCVinduced steatosis [3] . Interferonαbased therapy, in combination with ribavirin, has limited efficacy in approximately 50% of patients and is associated with severe side effects [4] . Directacting antivirals (DAAs) targeting NS3/4A, NS5A, and NS5B proteins can lead to higher sustained virological responses than interferonbased regimens, have shorter treatment duration, are orally administered, and have fewer side effects [5] . HCV is an enveloped RNA virus whose replication occurs in the cytoplasm. It consists of a singlestranded 9.6kb RNA genome of positive polarity with a 5' internal ribosome entry site (IRES). IRESdriven HCV RNA produces a polyprotein of approximately 3000 amino acids localized to the rough endoplasmic reticulum (ER), where it is cleaved into at least four structural proteins (C, E1, E2, and p7) and six nonstructural proteins (NS2, NS3, NS4A, NS4B, NS5A, and NS5B) that play a key role in viral replication, assembly, and pathogenesis [6] . Elucidation of the viral structure and virushost interaction is an important goal of antiHCV drug disco very and vaccine development [7] . HCV replicon system has contributed to the study of HCV in the human hepatoma cell line Huh7 [8, 9] . The infectious HCV JFH1 cell culture system represents a major advance in antiHCV drug discovery research [7, 1012] . This model generates infectious viral particles in cell culture (HCVcc) and facilitates the study of HCV life cycle [7, 11] . However, HCV JFH1 variant genome (genotype 2a) results in relatively low viral titers [7, 13, 14] . Several studies suggested that cell cultureadaptive mutations in HCV genomic RNA might potentially in crease the production of infectious HCV particles [13, 1518] . Recently, an adaptive HCV JFH1 reporter isolate designated as JFH1∆V3EGFP was identified [19] , which produced higher titers (10 6 focusforming units [FFUs]/ mL) of HCVEGFP reporter virus. Whole genome sequencing analysis showed that JFH1ΔV3EGFP included six mutations located in the E2, p7, NS4B, and NS5A regions as follows: D657G in E2; H781Y in p7; N1931S in NS4B; and C2274R, I2340T, and V2440L in NS5A. V2440L and H781Y improved the infectious HCV titers [20, 21] , while data pertaining to the other mutations are not available. In this study, we explored these mutations or combinations thereof responsible for enhanced viral production and investigated the underlying mechanisms.
MATERIALS AND METHODS

Cell culture
The human hepatoma cell line Huh7.5 was generously provided by Dr. Charles M. Rice [22] (Rockefeller University) and maintained in Dulbecco's modified Eagle's medium (DMEM) (Invitrogen) supplemented with 100 U/mL of penicillin, 100 µg/mL of streptomycin, nonessential amino acids, and 10% fetal bovine serum (Invitrogen) at 37 ℃ in 5% CO2. All the experiments described in this study were performed using these cells.
Antibodies
The monoclonal antibody to NS5A protein (Abcam), the goat antimouse IgG conjugated with horsera dish peroxidase (Sigma), and goat antimouse IgG conjugated with Alexa Fluor 594 (Invitrogen) were all obtained commercially.
Plasmid construction
Plasmid constructs were based on the consensus sequence of HCV pJFH1, which was kindly provided by Dr. Wakita [10] . JFH1∆V3EGFP and JFH1AM120 plasmids were kindly provided by Dr. C.H. Hagedorn and ShuangHu Liu [19] . The mutations located in HCV genomic RNA are shown in Figure 1 . A series of primers for construction of adaptive variants of wildtype HCV JFH1 listed in Table 1 were designed using the pJFH1 sequence and mutations. The pJFH1 plasmid was used as a template for subsequent PCR with Phushion High Fidelity PCR Master Mix with GC buffer (New England Biolabs) according to the manufacturer's instructions. The preliminary PCR products (mE21, mE22, mp71, mp72, mNS4B1, mNS4B2, mNS5A1, mNS5A2, mNS5A3, and mNS5A4) were analyzed by 1% agarose gel electrophoresis, and used for overlap PCR following the combination showed in Tables 2 and 3 to obtain adaptive mutation fragments. The above fragments (mE2, mp7, mNS4B, mNS5A, mE2/NS5A, mp7/NS5A, mNS4B/NS5A, and mE2/p7/NS5A) were subcloned into pJFH1 using the appropriate unique restriction enzyme sites such as Bsiw I, Kpn I, Nsi I, Rsr II, or BsrG I, to produce JFH1mE2, JFH1mp7, JFH1mNS4B, JFH1mNS5A, JFH1mE2/ NS5A, JFH1 mp7/NS5A, JFH1mNS4B/NS5A, JFH1mE2/p7/ NS5A, and also mJFH1, which contained all the six mutations. All new clones were sequenced using an ABI 3700XL (Shanghai Sangon Biotech).
Transfection with HCV RNA
To generate the fulllength genomic RNA, pJFH1 and all plasmids were linearized with Xba I. The linearized plasmid DNA was purified and then used as a template for T7 in vitro transcription (MEGAscript; Ambion). The RNA genomes were detected by formaldehyde agarose gel electrophoresis as described previously [23] , and transfected into cells by electroporation [13] .
Immunofluorescence assay
Cells seeded on glass coverslips were infected with HCV. After 48 h, the slips were washed with PBS. Then, the cells were fixed with 4% paraformaldehyde, permeabilized with 0.2% Triton X100, and blocked with 1% BSA and 1% normal goat serum. The NS5A in cells was detected with a monoclonal antibody and a secondary goat antimouse Alexa Fluor 594 antibody (Invitrogen) and visualized by fluorescence microscopy.
Virus titration
The titer of infectious HCV was determined by immuno fluorescence assay [7] . Virus titers from supernatants and cell lysates as well were determined using FFUs.
Cell lysates were prepared as described previously [24] . Briefly, cell pellets harvested after trypsinization were washed with PBS, resuspended in completed culture medium, and lysed in four freeze/thaw cycles at 80 ℃ and 37 ℃. The cell lysates were centrifuged at 4000 rpm for 5 min prior to inoculation into naïve Huh7.5 cells.
Virus titration analysis was conducted by serially diluting the cell supernatants or cell lysates 10fold in DMEM. The supernatants were used to infect 1 × 10 
Confocal laser scanning microscopy
Cells transfected with HCV RNA with adaptive muta tions were seeded onto 24well plates with cover slips. The cells were treated as previously described [13] . After 48 h, the cells were washed with PBS, fixed with 4% paraformaldehyde, and then permeabilized with 0.2% Triton X100. Fixed cells were blocked with 1% bovine serum albumin and 1% normal goat serum in PBS. Next, HCV NS5A was analyzed in cells using a NS5A monoclonal antibody and a secondary goat antimouse IgG conjugated with Alexa 488 (Invitrogen, dilution of 1:1000). LipidTOX Deep Red (Invitrogen) was used to detect neutral lipids present in lipid droplets (LDs). The slides were counterstained using DAPI (Invitrogen), and examined using an Zeiss LSM 510 Meta confocal laser scanning microscope.
RESULTS
Effect of individual mutations or combinations of adaptive mutations on the production of infectious HCV
A previous study demonstrated that JFH∆V3EGFP variant produces a higher titer of reporter virus [19] . The 
Western blot analysis
The Huh7.5 cells infected with HCV RNA were lysed in 50 mmol/L TrisHCl (pH 7.5) containing 150 mmol/L sodium chloride, 1% Nonidet P40, 0.5% sodium deoxycholate, 0.1% SDS, and proteinase inhibitors (Complete Mini, Roche). Samples were separated by 10% SDSPAGE and then transferred onto nitrocellulose membranes. The HCV NS5A (p56/p58) was analyzed as described previously [13] .
Quantification of HCV RNA by qPCR
Total RNA was extracted with TRIzol (Invitrogen). HCV RNA was measured by qPCR analysis as described previously [25] . βactin was used as the internal control. The relative quantity of HCV RNA in control and HCV samples was calculated by the comparative Ct (cycling threshold) method using LightCycler480. six adaptive mutations in this variant were located in the E2 (D657G), p7 (H781Y), NS4B (N1931S), and NS5A (C2274R, I2340T, and V2440L) ( Figure 1A ), respectively. To determine the individual or synergistic combination of these mutations responsible for the increased viral production, recombinant JFH1 genomes containing only one of the selected mutations or four different combinations as shown in Figure 1A were constructed. Next, ten in vitrotranscribed mutant JFH1 RNAs ( Figure 1B) were electroporated into Huh7.5 cells to produce recombinants of adapted virus. The transfected cells were subcultured every three days. The infectivity titers of supernatants at day 3 (P1) and day 9 (P3) were measured ( Figure 2 ). Viral titers are expressed as FFUs/mL and were assayed in duplicate, which was repeated three times. The data are presented as mean ± SD (n = 3). The HCV titers of wild type JFH1 (JFH1) were extremely low, with a typical titer of 10 2 FFUs/mL.
The adaptive mutations in E2, p7, NS4B, and NS5A individually increased the production of infectious HCV titers 2 to 4fold compared with the levels of JFH1. The NS5A mutations exhibited the greatest effect on the production of infectious HCV particles, with a titer of 1.30 × 10 6 FFUs/mL at P3. The p7 mutation followed closely, generating a titer of 2.10 × 10 5 FFUs/mL. Briefly, except for E2, the HCV titers of other variants at P3 were partially higher than those at P1.
To further determine any synergistic effect of the six adaptive mutations on HCV production, we focused on the recombinant viruses with adaptive mutations in different combinations. As shown in Figure 2 , JFH1 mE2/NS5A, JFH1mp7/NS5A, JFH1mNS4B/NS5A, and JFH1mE2/p7/NS5A remarkably enhanced the production of infectious HCV, and the mJFH1 produced infectious HCV particles with a robust titer of 1.61 × 10 6 FFUs/mL 9 d posttransfection.
These results suggest that all the six adaptive mutations increase the HCV particle production. NS5A (C2274R, I2340T, and V2440L) and p7 (H781Y) are the critical adaptive mutations.
HCV RNA replication and protein expression are upregulated by adaptive mutations HCV RNA genome replication and structural or non structural protein expression are early steps in the HCV life cycle. To further confirm our speculation that the robust HCV titers and enhanced virion release were both related to upregulated RNA replication and protein expression, we determined the relative HCV RNA, NS5A immunofluorescence, and NS3 protein levels in the RNAtransfected Huh7.5 cells on day 3 (P1) and day 9 (P3).
As shown in Figure 3 , the expression of NS5A ( Figure  3A ) and NS3 ( Figure 3B ) in mutants was upregulated at different levels during serial passages. The trend was extraordinary obvious in NS5A or p7 mutants. AntiNS3 Western blot analysis, which was the most widely used for quantitative experiment, yielded consistent results.
As shown in Figure 3C , the RNA levels of all the mutants were increased compared with JFH1, and mJFH1 was increased 18.7fold. Interestingly, the results indicated that JFH1mNS4B expression increased 6.1fold, and the combination of mutants showed a 7.416.8fold increase.
Taken together, we confirmed that the effect of NS5A (C2274R, I2340T and V2440L), p7 (H781Y), and NS4B (N1931S) on infectious HCV titers was robust, and started with HCV RNA replication and protein expression, followed by virion release.
Adapted variants enhance the efficiency of virus release
Virion release is the last step of the HCV life cycle. To further explore the mechanism underlying the enhanced virus production, the role of adaptive mutations was examined. Ten HCV RNAs (JFH1, JFH1mE2, JFH1 mP7, JFH1mNS4B, JFH1mNS5A, JFH1mE2/NS5A, JFH1mp7/NS5A, JFH1mNS4B/NS5A, mJFH1, and JFH1mE2/p7/NS5A) were electroporated into Huh7.5 cells. After 3 d, we collected the supernatants and cell lysates, and measured the HCV titers using NS5A immunofluorescence assays. Furthermore, to confirm the infectivity of virions, we carried out immunoblotting of supernatants and cell lysates with antiNS3, which was extraordinarily consistent with the infectious HCV titers ( Figure 4A ). As shown in Figure 4B , we also cal culated the proportion of extracellular (supernatant) or intracellular (cell lysate) HCV titers using total titers as 100%. Typically, the supernatant and intrace llular HCV titers of JFH1 were 76.31% and 23.69%, respectively, and those of mJFH1 were 94.00% and 6.00%, respectively. Taken together, these findings provide evidence suggesting that the ten variant viruses enhanced the virion release, and the high viral production was linked to the effective virion release. NS5A (C2274R, I2340T, and V2440L) and p7 (H781Y) showed the highest levels compared with the others.
Adaptive mutations are not essential for intracellular LD localization of the NS5A protein
LDs have been reported to play an important role in the HCV virion assembly process [26] . To determine if the six adaptive mutations increased the assembly of HCV at this step, LDs and NS5A were stained in JFH1 and mJFH1 transfected cells and the colocalization of LDs with NS5A was measured. As shown in Figure 5 , the LDs were totally covered with NS5A in all cases. However, no significant difference was observed between JFH1 and mJFH1 groups using Image J software and Pearson' s correlation coefficient analysis. These results indicated that the six adaptive mutations were not required for LD localization of the NS5A proteins.
Adapted mutations do not affect hyper-phosphorylation of NS5A
Previous studies showed that a ratio between the p56 and p58 phosphoforms of NS5A is required for optimal HCV RNA replication [13, 2729] . JFH1AM120 is a robust adaptive mutant selected by Liu et al [13] . which displays significant switch of p56/p58. In this study, JFH1, JFH1 AM120, and mJFH1 RNA were transfected into Huh7.5 cells, and the total protein was used for Western blot analysis after 3 d (Figure 6 ). However, we observed no difference in p56 and p58 between the two groups.
These results demonstrated that the phosphorylation level of NS5A was not affected by adaptive mutations.
DISCUSSION
Previous studies suggested that in vitro adaptive mutations enhance the production of infectious virus [1317, 20, 21, 3034] . A high mutation rate in HCV RNA genome is a challenge for successful HCV treatment and vaccine research, although a method to obtain a robust clonal culture of HCV has been unavailable [13] . Liu et al [19] demonstrated that a JFH1∆V3EGFP variant produced higher titer of reporter virus. The six adaptive mutations in this variant were located in the E2 (D657G), p7 (H781Y), NS4B (N1931S), and NS5A (C2274R, I2340T, and V2440L) ( Figure 1A ). However, the mutations responsible for enhanced viral production were not clear. The six mutations in this study were simultaneously located in JFH1∆V3EGFP, which was a reporter EGFP gene chimera virus [19] . The mJFH1 refers to JFH1ΔV3EGFP that yielded a robust titer up to 1.61 × 10
6 FFUs/mL in this study, suggesting that the six mutations are effective adaptive mutations. HCV is a single, positivestrand RNA virus. We focused on key life cycle events in the virus such as replication, expression, assembly, and release. Infectious virion release is the last step and the final objective of the JFH1 system. In our study, we detected variant virus titers initially. Consistent with previous reports [7, 14] , JFH1 only exhibited a decreased titer of 10 2 FFUs/mL.
The other mutants showed increased titers with several orders of magnitude compared with JFH1. Synergistic enhancement of HCV titer was demonstrated obviously. Jiang et al [35] suggested that adaptive mutations en hance specific proteinprotein interactions among viral proteins and promote the assembly of infectious HCV particles. We speculated that the six mutations involved refer to unknown life cycle phases and mechanism as well. Therefore, we analyzed the effect of viral mutations on the distribution of virions in the supernatant and the cell lysate, colocalization of LDs and NS5A, HCV RNA level, NS3 expression, and p56/p58. We found that the adaptive mutations were associated with diverse effects on the life cycle events. The virion release and RNA genome replication were specifically associated with NS5A and p7 mutations. The transmembrane domains of chimeric E1 and/or E2 HCV glycoproteins were modified to allow transport to and assembly at the cell surface [36] . E2 consisted of three critical domains: a receptorbinding domain (RBD; residues 384661), the membrane proximal stemlike region of E2 (residues 675699), and a hydrophobic heptad repeat linking the two domains [37] . Within the RBD, the E2 bound the cellular receptor CD81, leading to receptormediated endocytosis of virions [38, 39] . Serial studies showed that the mutations in E2 play a role in the HCV life cycle via different mechanisms. Tao et al [30] demonstrated that the E2 (I414T) mutation had no significant effect on HCV RNA replication and viral entry. However, it enhanced the production of infectious viral particles and decreased the receptormediated viral entry. E2 (G451R) altered the relationship between particle density and infectivity, disrupted the co receptor dependence, and increased virion sensitivity to receptor mimics [40] . The T563I mutation in the E2 protein increased virion viability at 37 ℃. Unfortunately, D657G in E2 improved the HCV titer via an unknown mechanism, without any effect on HCV RNA replication or virion release.
As a small membrane polypeptide, the HCV p7 channel plays multiple roles in virus life cycle and mediates several biological functions in HCV infection [41] . The p7 consists of six equivalent hydrophobic pockets between the peripheral and poreforming helices [42] . Generally, p7 is not essential for HCV RNA replication, but required for virion assembly and release [43] . The adaptive mutation N765D in p7 influenced early stages of the HCV life cycle, and increased the infectious HCV titer [15] . Y781H enhances the level of HCV core in the supernatant three to fivefold, and moderately increases virion assembly and release [21] . In our study, we found similar results, and Y781H enhanced HCV RNA replication 3.1fold, suggesting its role as a critical initiating agent and a novel mechanism during the HCV life cycle.
HCV NS4B plays an important role in RNA genome replication and virion assembly [44] . NS4B triggers the formation of a viral replication complex [45] similar to the "spongelike inclusions" observed in the liver of HCV infected chimpanzee [46] . NS4B (K1846T) increased HCV RNA replication nearly 30fold [47] . N1931S is located between helices 1 and 2 of the NS4B Cterminus, and was first determined by Li et al [48] during HCV RNA replication and virion assembly. Our data suggested that the N1931S increased HCV titer to 10 3 FFUs/mL, which was 10 3 fold compared with JFH1. It significan tly enhanced HCV genome replication, and slightly improved virion release. N1931S is a novel mutation in the JFH1 system, and comprehensive studies inve stigating its role in HCV infection are needed.
HCV NS5A is a phosphoprotein existing in two different forms: a basic phosphorylated NS5A, p56, and a hyperphosphorylatedNS5A, p58. It appears to play an important role in viral replication, since most of the adaptive mutations determined so far are located within the region of NS5A [47] . The three domains in NS5A include: domain I (aa 28213) coordinating a single zinc atom, and domains II (aa 250342) and III (aa 356447), which are less well characterized but are important in RNA replication and/or virion assembly [28] . A previous report suggested that V2440L was located at the NS5AB cleavage site and decreased the cleavage kinetics [20] . Thus, the mutation C2274R is located in domain II, and the other mutations (I2340T and V2440L) occur in domain III. We analyzed the HCV RNA replication and protein expression. The results showed that the three mutations enhanced HCV RNA replication, Figure 5 Colocalization analysis of lipid droplets and hepatitis C virus NS5A. JFH1 and mJFH1 RNA was electroporated into Huh7.5 cells to produce the recombinants of adapted virus. At 48 h after transfection, the cells were fixed. Lipid droplets were stained with LipidTOXRed (Red). The HCV NS5A was stained with anti-NS5A antibody (Green). The nucleus was stained with DAPI (Blue). Each triplicate sample of 25 cells was analyzed using Image J software. The degree of colocalization was quantified and compared using Pearson's correlation coefficients.
which is consistent with the structure.
A previous study demonstrated that HCV p7 pro motes a late step of assembly and release of infectious virions [49] and NS5A plays a major role in regulating the release of infectious virus particles in cell culture [32] . In this study, there were three mutants (C2274R, I2340T, and V2440L) located in NS5A and one located (H781Y) in p7. Our results showed that these mutants obviously promoted the HCV viral particles release (Figure 4) . HCV core is located on the cytosolic side of the ER membrane, assembly probably initiates in the cytosol before further maturation, and release occurs by transfer of nascent particles across the ER membrane to enable access to the secretory pathways in hepatocytes [50] . The amino acid changes induced by mutants in NS5A and P7 may be involved in these steps. The specific mechanism needs to be further studied in future.
Previous studies suggested that the upregulation of p56/p58 ratio might be a critical factor for HCV titer [13] and increased HCV replication since specific mutations reduced NS5A hyperphosphorylation activating RNA replication [27] . NS5Ap58 levels increased following overexpression of CKIalpha, CKIdelta, and CKI epsilon, whereas RNA interference of CKIalpha alone reduced NS5A hyperphosphorylation [51] . Here, we detected the status of p56/p58. However, there was no switch between the JFH1 and mJFH1 groups. The two viral proteins including the core and NS5A were localized to LDs, which play an important role in the intracellular assembly of HCV [24, 26] . The recruitment of NS5A to LDs was a prerequisite for virion assembly in Huh7.5 cells [26] . Our analysis of the colocalization of NS5A and LDs showed no significant difference between mJFH1 and JFH1, suggesting that these adaptive mutations did not alter virion formation.
The life cycle of HCV is extremely complex, and several details remain unknown. Regulation of host gene expression [52, 53] , altered association between viral proteins and/or hostcell proteins, and changes in virus per se [54] represent obvious mechanisms. In our study, we confirmed that the adaptive mutations led to a robust infectious titer via enhanced viral replication and release. It is recommended that DAA regimens can be used for treatment of patients with hepatitis C rather than pegylated interferon/rabivirin [5] . Meanwhile, our study was limited by the reaction of DAAs to above adaptive mutations. Further studies investigating the underlying mechanisms of viral morphogenesis are needed.
In conclusion, we generated infectious HCV particles with a robust titer of 1.61 × 10
6 FFUs/mL in this study.
All of the six adaptive mutations increased the HCV particle production at varying levels. The NS5A (C2274R, I2340T, and V2440L) and p7 (H781Y) were critical adaptive mutations. This study confirmed that the JFH1 is still a promising system to study the HCV life cycle. To use adaptive mutations is an effective means to establish a new system with higher infectious HCV virions titer. And the research on molecular mechanism of interaction between viral proteins and/or hostcell proteins should be carried out in depth.
ARTICLE HIGHLIGHTS
Research background
Hepatitis C virus (HCV) causes acute and chronic hepatitis, and leads to permanent liver damage and hepatocellular carcinoma. The infectious HCV JFH1 cell culture system represents a major advance in anti-HCV drug discovery research and facilitates the study of HCV life cycle. However, HCV JFH1 (genotype 2a) merely generates relatively low viral titers. JFH1-∆V3-EGFP, which includes six mutations located in the E2, p7, NS4B, and NS5A regions, could produce higher titers of HCV-EGFP reporter virus. However, there were no data about which mutations or combinations thereof are responsible for enhanced viral production and the underlying mechanisms.
Research motivation
This JFH1 model generated infectious viral particles in cell culture and facilitated the study of the HCV life cycle, but the low infectious virion titer limits Figure 6 Phosphorylation of NS5A during JFH1 and mJFH1 replication. Huh7.5 cells were transfected with JFH1 or mJFH1 RNA. After three days of culture, cells were lysed for western blot using anti-NS5A and anti-β-actin antibodies. The quantity of p56 and p58 was determined using Image J software and the ratios of p56/p58 are shown. Data are presented as mean ± SD (n = 3). JFH1-AM120 was used as the positive control.
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its application range. Some previous studies have confirmed that adaptive mutations could enhance the virion titer, but the mechanism has not yet been fully elucidated. In this study, we focused on the positive effect of six adaptive mutations located in the E2, p7, NS4B, and NS5A regions, and found that the mechanism was different among them during the procession. These results gave us some new insights into the infectious HCV cell culture system and adaptive mutations.
Research objectives
The main objective of this study was to establish an infectious HCV cell culture system with a robust titer, and to discuss the underlying mechanisms of the adaptive mutations found in previous studies. The results of this study have supplied the researchers with a useful tool. We hope it will be used for the study of viral structure, virus-host interaction, anti-HCV drug discovery, and vaccine development.
Research methods
We investigated JFH1-mE2, JFH1-mp7, JFH1-mNS4B, JFH1-mNS5A, JFH1-mE2/NS5A, JFH1-mp7/NS5A, JFH1-mNS4B/NS5A, JFH1-mE2/p7/ NS5A, and mJFH1, carrying all the six mutations. We analyzed the infectious HCV titer, HCV RNA and NS3 protein levels, viral release capacity, assembly and hyperphosphorylation of NS5A to determine the role of these mutations in the HCV life cycle. These methods were the routine ways adopted widely in virological and molecular biological research.
Research results
The main findings in this study were as follows: (1) we generated infectious HCV particles with a robust titer of 1.61 × 10 6 FFUs/mL; (2) The six adaptive mutations increased the HCV particle production at varying levels. The NS5A (C2274R, I2340T, and V2440L) and p7 (H781Y) are critical adaptive mutations. The effect of NS5A (C2274R, I2340T, and V2440L), p7 (H781Y), and NS4B (N1931S) on infectious HCV titers was investigated by measuring the HCV RNA replication, protein expression, and virion release; and (3) the six adaptive mutations were all not required for the lipid droplet localization of NS5A proteins or the phosphorylation of NS5A. To our knowledge, this is a new robust titer related to adaptive mutations from JFH1. The problems that remain to be solved in the future include: (1) how could the adaptive mutations be translated to clinical conditions? (2) are these mutation patterns observed in vivo? and (3) would these results be relevant to the resistance to direct-acting antivirals (DAAs)?
Research conclusions
First, this study generated infectious HCV particles with a robust titer of 1.61 × 10 6 FFUs/mL. Second, all of the six adaptive mutations increased the HCV particle production at varying levels. Third, the NS5A (C2274R, I2340T, and V2440L) and p7 (H781Y) were critical adaptive mutations, but they were not required for the LD localization of NS5A proteins or the phosphorylation of NS5A. Based on the new findings of this study, we proposed that more important adaptive mutations would be addressed in the future, and unknown mechanism of the HCV life cycle would be explained.
Research perspectives
This study re-confirmed that the JFH1 was still a promising system to study the HCV life cycle. To use adaptive mutations was an effective way to establish a new system with higher infectious HCV virion titer. In addition, we also reconfirmed that the molecular mechanism of interaction between viral proteins and/or host-cell proteins is more complex and important.
